All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub was pleased to speak to Mark R. Litzow, Mayo Clinic, Rochester, US. We asked, Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult patients with B-ALL in MRD⁻ remission?
Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult with B-ALL in MRD⁻ remission?
Litzow provides an update on the results from the ECON-ACRIN E1910 randomized phase III trial of blinatumomab on behalf of the National Cooperative Clinical Trial Network. He then discusses how the addition of blinatumomab to consolidation chemotherapy can improve overall survival in patients with newly diagnosed B-ALL who were MRD-negative after intensification chemotherapy without any safety concerns. He concludes that the addition of blinatumomab to consolidation chemotherapy represents a new standard of care for adult patients with MRD-negative B-ALL.
Blinatumomab in newly diagnosed adult patients with ALL in MRD negative remission: Results from ECON-ACRIN E1910
The addition of blinatumomab to consolidation chemotherapy resulted in improved overall survival in patients with newly diagnosed B-ALL...
Blinatumomab prior to CD19 CAR T-cell therapy for the treatment of relapse/refractory ALL
Regulatory agencies in Europe and the United States have approved two agents that target CD19 for the treatment of relapsed/refractory acute lymphoblastic...
Subscribe to get the best content related to ALL delivered to your inbox